Syneron Medical Ltd.  

(Public, NASDAQ:ELOS)   Watch this stock  
Find more results for ELOS
+0.25 (2.91%)
Jan 13 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.60 - 8.85
52 week 6.11 - 9.10
Open 8.60
Vol / Avg. 261,668.00/197,138.00
Mkt cap 316.12M
P/E 103.34
Div/yield     -
EPS 0.09
Shares 35.27M
Beta 1.05
Inst. own 64%
Feb 22, 2017
Q4 2016 Syneron Medical Ltd Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2016
Syneron Medical Ltd at Canaccord Genuity Med Tech Conference
Nov 9, 2016
Q3 2016 Syneron Medical Ltd Earnings Release
Nov 9, 2016
Q3 2016 Syneron Medical Ltd Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin 0.82% -2.28%
Operating margin 2.02% -2.32%
EBITD margin - 2.30%
Return on average assets 0.85% -2.14%
Return on average equity 1.13% -2.90%
Employees 784 -
CDP Score - -


Tavor Building 4 P.O. Box 550
YOKNEAM, 2069200
+972-7-32442200 (Phone)
+972-7-32442202 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Syneron Medical Ltd. is engaged in the manufacture, research, development, marketing and sale of equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology, which uses the synergy between electrical energy, including radiofrequency (RF) energy, and optical energy to provide aesthetic medical treatments. Its products target an array of non-invasive aesthetic medical procedures, including hair removal, wrinkle reduction, tattoo removal, rejuvenation of the skin's appearance through the treatment of superficial benign vascular and pigmented lesions, acne treatment, treatment of leg veins, treatment for the temporary reduction in the appearance of cellulite and thigh circumference, ablation and resurfacing of the skin, and laser-assisted lipolysis.

Officers and directors

Shimon Eckhouse Ph.D. Chairman of the Board
Age: 69
Bio & Compensation  - Reuters
Amit Meridor Chief Executive Officer
Bio & Compensation  - Reuters
Hugo Goldman Chief Financial Officer
Bio & Compensation  - Reuters
Erik Dowell Vice President-North America
Age: 43
Bio & Compensation  - Reuters
William Griffing Chief Executive Officer - Syneron Candela North America
Age: 48
Bio & Compensation  - Reuters
Shlomo Alkalay Chief Operating Officer
Age: 51
Bio & Compensation  - Reuters
Robert Ruck Executive Vice President, Asia Pacific
Age: 54
Bio & Compensation  - Reuters
Robert Fielitz Vice President and Managing Director of Europe, Middle East and Africa
Age: 46
Bio & Compensation  - Reuters
Sarit Soccary Ben-Yochanan Vice President - Business Development & Strategy
Age: 44
Bio & Compensation  - Reuters
Ilan Nacasch Chief Branding Officer
Age: 41
Bio & Compensation  - Reuters